Severe Pseudomonas aeruginosa infections

References

• Jarvis WR. Epidemiology and control of Pseudomonas aeruginosa infections in the intensive care unit. In: Hauser AR, Rello J, eds. Severe infections caused by Pseudomonas aeruginosa. Boston: Kluwer Academic, 2003: 153–68
   Google Scholar
• Piddock LJ, Johnson M, Ricci V, et al. Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract. Antimicrob Agents Chemother 1998: 42(11): 2956–60
   PubMed Web of Science ®Google Scholar
• Weinstein RA, Nathan C, Gruensfelder R, et al. Endemic aminoglycoside resistance in gram-negative bacilli: epidemiology and mechanisms. J Infect Dis 1980; 141(3): 338–45
   Web of Science ®Google Scholar
• Gales AC, Jones RN, Turnidge J, et al. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin Infect Dis 2001; 32 Suppl 2: S146–55
   PubMedGoogle Scholar
• Fridkin SK, Steward CD, Edwards JR, et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 1999; 29(2): 245–52
   PubMed Web of Science ®Google Scholar
• Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003; 289(7): 885–8
   PubMed Web of Science ®Google Scholar
• Fekete T, Tumah H, Woodwell J, et al. Comparative susceptibilities of Klebsiella species, Enterobacter species, and Pseudomonas aeruginosa to 11 antimicrobial agents in a tertiary-care university hospital. Am J Med 1996; 100(6A): 20–5S
   Google Scholar
• Itokazu GS, Quinn JP, Bell-Dixon C, et al. Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program. Clin Infect Dis 1996; 23(4): 779–84
   PubMed Web of Science ®Google Scholar
• Spencer RC. An 8 year Microbe Base survey of the epidemiology, frequency and antibiotic susceptibility of Pseudomonas aeruginosa hospital isolates in the United Kingdom. J Antimicrob Chemother 1996; 37(2): 295–301
   Google Scholar
• Lode H, Wiley R, Hoffken G, et al. Prospective randomized controlled study of ciprofloxacin versus imipenem-cilastatin in severe clinical infections. Antimicrob Agents Chemother 1987; 31 (10): 1491–6
   PubMed Web of Science ®Google Scholar
• Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother 1994; 38(3): 547–57
   Google Scholar
• Torres A, Bauer TT, Leon-Gil C, et al. Treatment of severe nosocomial pneumonia: a prospective randomised comparison of intravenous ciprofloxacin with imipenem/cilastatin. Thorax 2000; 55(12): 1033–9
   Google Scholar
• Crouch Brewer S, Wunderink RG, Jones CB, et al. Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 1996; 109(4): 1019–29
   Google Scholar
• Rello J, Gallego M, Mariscal D, et al. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997; 156(1): 196–200
   Google Scholar
• Troillet N, Samore MH, Carmeli Y. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin Infect Dis 1997; 25(5): 1094–8
   Google Scholar
• El Amari EB, Chamot E, Auckenthaler R, et al. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis 2001; 33(11): 1859–64
   Google Scholar
• Carmeli Y, Troillet N, Eliopoulos GM, et al. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999; 43(6): 1379–82
   PubMed Web of Science ®Google Scholar
• Chandrasekar PH, Crane LR, Bailey EJ. Comparison of the activity of antibiotic combinations in vitro with clinical outcome and resistance emergence in serious infection by Pseudomonas aeruginosa in non-neutropenic patients. J Antimicrob Chemother 1987; 19(3): 321–9
   Google Scholar
• Hilf M, Yu VL, Sharp J, et al. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989; 87(5): 540–6
   PubMed Web of Science ®Google Scholar
• Jacobson KL, Cohen SH, Inciardi JF, et al. The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in group I β-lactamase-producing organisms. Clin Infect Dis 1995; 21(5): 1107–13
   Google Scholar
• Chamot E, Boffi El Amari E, Rohner P, et al. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2003; 47(9): 2756–64
   PubMed Web of Science ®Google Scholar
• Vidal F, Mensa J, Almela M, et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment: analysis of 189 episodes. Arch Intern Med 1996; 156(18): 2121–6
   Google Scholar
• Leibovici L, Paul M, Poznanski O, et al. Monotherapy versus β-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 1997; 41(5): 1127–33 [Erratum, Antimicrob Agents Chemother 1997; 41(10: 2595]
   PubMed Web of Science ®Google Scholar
• Harris A, Torres-Viera C, Venkataraman L, et al. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin Infect Dis 1999; 28(5): 1128–33
   PubMed Web of Science ®Google Scholar
• Stein A, Raoult D. Colistin: An antimicrobial for the 21st century? Clin Infect Dis 2002; 35(7): 901–2
   Google Scholar
• Levin AS, Barone AA, Penco J, et al. Intravenous Colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28(5): 1008–11
   PubMed Web of Science ®Google Scholar